Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Short report

Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early Hepatocellular carcinoma in patients with cirrhosis

Authors: Yantong Guo, Jingming Zhao, Jingtao Bi, Quan Wu, Xin Wang, Quanyou Lai

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors occurring mainly in patients with chronic liver disease. Detection of early HCC is critically important for treatment of these patients.

Methods

We employed a proteomic profiling approach to identify potential biomarker for early HCC detection. Based on Barcelona Clinic Liver Cancer (BCLC) staging classification, 15 early HCC and 25 late HCC tissue samples from post-operative HCC patients and their clinicopathological data were used for the discovery of biomarkers specific for the detection of early HCC. Differential proteins among cirrhotic, early, and late tissue samples were separated by two-dimensional gel electrophoresis (2-DE) and subsequently identified by mass spectrometry (MS). Receiver operating characteristic (ROC) curves analysis were performed to find potential biomarkers associated with early HCC. Diagnosis performance of the biomarker was obtained from diagnosis test.

Results

Protein spot SSP2215 was found to be significantly overexpressed in HCC, particularly in early HCC, and identified as heterogeneous nuclear ribonucleoprotein K (hnRNP K) by tandem mass spectrometry (MALDI TOF/TOF). The overexpression in HCC was subsequently validated by western blot and immunohistochemistry. ROC curve analysis showed that hnRNP K intensity could detect early HCC at 66.67 % sensitivity and 84 % specificity, which was superior to serum α-fetoprotein (AFP) in detection of early HCC. Furthermore, the diagnosis test demonstrated, when combined with hnRNP K and serum AFP as biomarker panel to detect early HCC at different cut-off value, the sensitivity and specificity could be enhanced to 93.33 % and 96 %, respectively.

Conclusions

hnRNP K is a potential tissue biomarker, either alone or in combination with serum AFP, for detection of early HCC. High expression of hnRNP K could be helpful to discriminate early HCC from a nonmalignant nodule, especially for patients with liver cirrhosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bosch FX, Ribes J, Cleries R, Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005, 9: 191-211. 10.1016/j.cld.2004.12.009. v.CrossRefPubMed Bosch FX, Ribes J, Cleries R, Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005, 9: 191-211. 10.1016/j.cld.2004.12.009. v.CrossRefPubMed
2.
go back to reference Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH: Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol. 2001, 7: 208-215.PubMed Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH: Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol. 2001, 7: 208-215.PubMed
3.
go back to reference Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002, 35: 519-524. 10.1053/jhep.2002.32089.CrossRefPubMed Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002, 35: 519-524. 10.1053/jhep.2002.32089.CrossRefPubMed
4.
go back to reference Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB: Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002, 36: S84-S92.CrossRefPubMed Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB: Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002, 36: S84-S92.CrossRefPubMed
5.
go back to reference Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology. 2005, 42: 1208-1236. 10.1002/hep.20933.CrossRefPubMed Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology. 2005, 42: 1208-1236. 10.1002/hep.20933.CrossRefPubMed
6.
go back to reference Sherman M: Alphafetoprotein: an obituary. J Hepatol. 2001, 34: 603-605. 10.1016/S0168-8278(01)00025-3.CrossRefPubMed Sherman M: Alphafetoprotein: an obituary. J Hepatol. 2001, 34: 603-605. 10.1016/S0168-8278(01)00025-3.CrossRefPubMed
7.
go back to reference Daniele B, Bencivenga A, Megna AS, Tinessa V: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004, 127: S108-S112. 10.1053/j.gastro.2004.09.023.CrossRefPubMed Daniele B, Bencivenga A, Megna AS, Tinessa V: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004, 127: S108-S112. 10.1053/j.gastro.2004.09.023.CrossRefPubMed
8.
go back to reference Rapaccini GL, Pompili M, Caturelli E, Covino M, Lippi ME, Beccaria S, Cedrone A, Riccardi L, Siena DA, Gasbarrini G: Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int. 2004, 24: 124-130. 10.1111/j.1478-3231.2004.0903.x.CrossRefPubMed Rapaccini GL, Pompili M, Caturelli E, Covino M, Lippi ME, Beccaria S, Cedrone A, Riccardi L, Siena DA, Gasbarrini G: Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int. 2004, 24: 124-130. 10.1111/j.1478-3231.2004.0903.x.CrossRefPubMed
9.
go back to reference Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994, 19: 61-66. 10.1002/hep.1840190111.CrossRefPubMed Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994, 19: 61-66. 10.1002/hep.1840190111.CrossRefPubMed
10.
go back to reference Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000, 95: 1036-1040.PubMed Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000, 95: 1036-1040.PubMed
11.
go back to reference Kondo T: Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB Rep. 2008, 41: 626-634. 10.5483/BMBRep.2008.41.9.626.CrossRefPubMed Kondo T: Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB Rep. 2008, 41: 626-634. 10.5483/BMBRep.2008.41.9.626.CrossRefPubMed
12.
go back to reference Elrick MM, Walgren JL, Mitchell MD, Thompson DC: Proteomics: recent applications and new technologies. Basic Clin Pharmacol Toxicol. 2006, 98: 432-441. 10.1111/j.1742-7843.2006.pto_391.x.CrossRefPubMed Elrick MM, Walgren JL, Mitchell MD, Thompson DC: Proteomics: recent applications and new technologies. Basic Clin Pharmacol Toxicol. 2006, 98: 432-441. 10.1111/j.1742-7843.2006.pto_391.x.CrossRefPubMed
13.
go back to reference Befeler AS, Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002, 122: 1609-1619. 10.1053/gast.2002.33411.CrossRefPubMed Befeler AS, Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002, 122: 1609-1619. 10.1053/gast.2002.33411.CrossRefPubMed
14.
go back to reference Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362: 1907-1917. 10.1016/S0140-6736(03)14964-1.CrossRefPubMed Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362: 1907-1917. 10.1016/S0140-6736(03)14964-1.CrossRefPubMed
15.
go back to reference Sasse EA: Objective evaluation of data in screening for disease. Clin Chim Acta. 2002, 315: 17-30. 10.1016/S0009-8981(01)00710-0.CrossRefPubMed Sasse EA: Objective evaluation of data in screening for disease. Clin Chim Acta. 2002, 315: 17-30. 10.1016/S0009-8981(01)00710-0.CrossRefPubMed
16.
go back to reference Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY: Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics. 2005, 5: 4581-4588. 10.1002/pmic.200401309.CrossRefPubMed Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY: Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics. 2005, 5: 4581-4588. 10.1002/pmic.200401309.CrossRefPubMed
17.
go back to reference Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST: Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics. 2008, 7: 315-325.CrossRefPubMed Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST: Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics. 2008, 7: 315-325.CrossRefPubMed
18.
go back to reference Michael WM, Eder PS, Dreyfuss G: The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein. EMBO J. 1997, 16: 3587-3598. 10.1093/emboj/16.12.3587.PubMedCentralCrossRefPubMed Michael WM, Eder PS, Dreyfuss G: The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein. EMBO J. 1997, 16: 3587-3598. 10.1093/emboj/16.12.3587.PubMedCentralCrossRefPubMed
19.
go back to reference Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI: The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 2006, 1765: 85-100.PubMed Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI: The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 2006, 1765: 85-100.PubMed
20.
go back to reference Michelotti EF, Tomonaga T, Krutzsch H, Levens D: Cellular nucleic acid binding protein regulates the CT element of the human c-myc protooncogene. J Biol Chem. 1995, 270: 9494-9499. 10.1074/jbc.270.16.9494.CrossRefPubMed Michelotti EF, Tomonaga T, Krutzsch H, Levens D: Cellular nucleic acid binding protein regulates the CT element of the human c-myc protooncogene. J Biol Chem. 1995, 270: 9494-9499. 10.1074/jbc.270.16.9494.CrossRefPubMed
21.
go back to reference Tomonaga T, Michelotti GA, Libutti D, Uy A, Sauer B, Levens D: Unrestraining genetic processes with a protein-DNA hinge. Mol Cell. 1998, 1: 759-764. 10.1016/S1097-2765(00)80075-1.CrossRefPubMed Tomonaga T, Michelotti GA, Libutti D, Uy A, Sauer B, Levens D: Unrestraining genetic processes with a protein-DNA hinge. Mol Cell. 1998, 1: 759-764. 10.1016/S1097-2765(00)80075-1.CrossRefPubMed
22.
go back to reference Moumen A, Masterson P, O'Connor MJ, Jackson SP: hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell. 2005, 123: 1065-1078. 10.1016/j.cell.2005.09.032.CrossRefPubMed Moumen A, Masterson P, O'Connor MJ, Jackson SP: hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell. 2005, 123: 1065-1078. 10.1016/j.cell.2005.09.032.CrossRefPubMed
23.
go back to reference Ng LF, Chan M, Chan SH, Cheng PC, Leung EH, Chen WN, Ren EC: Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication. PLoS Med. 2005, 2: e163-10.1371/journal.pmed.0020163.PubMedCentralCrossRefPubMed Ng LF, Chan M, Chan SH, Cheng PC, Leung EH, Chen WN, Ren EC: Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication. PLoS Med. 2005, 2: e163-10.1371/journal.pmed.0020163.PubMedCentralCrossRefPubMed
24.
go back to reference Ostrowski J, Bomsztyk K: Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer. 2003, 89: 1493-1501. 10.1038/sj.bjc.6601250.PubMedCentralCrossRefPubMed Ostrowski J, Bomsztyk K: Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer. 2003, 89: 1493-1501. 10.1038/sj.bjc.6601250.PubMedCentralCrossRefPubMed
25.
go back to reference Hsieh TY, Matsumoto M, Chou HC, Schneider R, Hwang SB, Lee AS, Lai MM: Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. J Biol Chem. 1998, 273: 17651-17659. 10.1074/jbc.273.28.17651.CrossRefPubMed Hsieh TY, Matsumoto M, Chou HC, Schneider R, Hwang SB, Lee AS, Lai MM: Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. J Biol Chem. 1998, 273: 17651-17659. 10.1074/jbc.273.28.17651.CrossRefPubMed
26.
go back to reference Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B, Truini M, Introini C, Puppo P, Ferrari N, Carmignani G, Boccardo F, Balbi C: Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer. 2009, 100: 1608-1616. 10.1038/sj.bjc.6605057.PubMedCentralCrossRefPubMed Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B, Truini M, Introini C, Puppo P, Ferrari N, Carmignani G, Boccardo F, Balbi C: Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer. 2009, 100: 1608-1616. 10.1038/sj.bjc.6605057.PubMedCentralCrossRefPubMed
27.
go back to reference Zhou R, Shanas R, Nelson MA, Bhattacharyya A, Shi J: Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Int J Cancer. , 126: 395-404. Zhou R, Shanas R, Nelson MA, Bhattacharyya A, Shi J: Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Int J Cancer. , 126: 395-404.
28.
go back to reference Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer. 2006, 95: 921-927. 10.1038/sj.bjc.6603349.PubMedCentralCrossRefPubMed Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer. 2006, 95: 921-927. 10.1038/sj.bjc.6603349.PubMedCentralCrossRefPubMed
Metadata
Title
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early Hepatocellular carcinoma in patients with cirrhosis
Authors
Yantong Guo
Jingming Zhao
Jingtao Bi
Quan Wu
Xin Wang
Quanyou Lai
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-37

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine